First Module of Rolling FDA Application Submitted for Rare Skin Condition Drug

Dr. Rachel Mendez MD, Medical Science Writer

✨ Why this is good news

Microcystic lymphatic malformations are a rare genetic skin condition causing painful, leaking lesions that currently have no approved treatment.

First ever FDA application.Before this, no treatment had ever been submitted for FDA approval for microcystic lymphatic malformations. This submission starts the official review process, bringing patients closer to the very first approved therapy.
Targets the root cause.QTORIN rapamycin gel directly blocks the malfunctioning PI3K/mTOR signaling pathway that drives the disease. Older treatments only managed symptoms, but this drug addresses the underlying genetic cause of the malformed lesions.
Topical gel avoids side effects.Because QTORIN is applied as a gel directly to the skin, it delivers the drug locally rather than throughout the body. This means patients could avoid the severe side effects often caused by oral rapamycin, such as mouth sores or immune suppression.
Rolling submission speeds access.The FDA allows Palvella to submit application modules as they are completed, rather than waiting for the entire package. This rolling review process can accelerate the timeline for approval, potentially getting this treatment to tens of thousands of suffering Americans faster.

The first piece of a regulatory application has been submitted to the U.S. Food and Drug Administration for a potential first approved treatment for a rare, debilitating skin condition that affects tens of thousands of Americans. Palvella Therapeutics announced it has delivered the initial module of a rolling New Drug Application for QTORIN rapamycin, a gel designed to treat microcystic lymphatic malformations, a genetic disease that causes painful, leaking skin lesions.

Microcystic lymphatic malformations are driven by a malfunction in the PI3K/mTOR signaling pathway, which causes malformed lymphatic vessels to protrude through the skin, leak fluid, bleed, and lead to recurrent infections and hospitalizations. There are currently no FDA-approved therapies for the estimated more than 30,000 people diagnosed with the condition in the United States. The Phase 3 SELVA study showed that QTORIN rapamycin produced highly statistically significant improvements across the primary endpoint, a key secondary endpoint, and all prespecified secondary endpoints. The drug was also well tolerated, supporting its potential as a targeted treatment that delivers rapamycin directly to diseased skin tissue while minimizing systemic side effects.

Because the FDA previously granted Breakthrough Therapy and Fast Track designations for QTORIN rapamycin, the agency can begin reviewing completed sections of the application before the full package is submitted. This rolling review process is designed to speed up evaluation for therapies addressing serious unmet medical needs. Palvella remains on track to complete the full NDA submission in the second half of 2026. If approved, the company is preparing for a potential standalone commercial launch in the first half of 2027, having already recruited leadership with experience launching first in disease therapies for rare skin conditions.

In March 2026, the company launched the BEYOND mLM awareness campaign in collaboration with patient advocacy groups to improve early diagnosis and educate specialists at vascular anomaly centers. The company is also building its field commercial and medical affairs teams to support a swift rollout. “Initiating the rolling NDA submission represents an important milestone in advancing QTORIN rapamycin toward potential approval for patients living with microcystic LMs,” said Jeff Martini, Ph.D., Chief Scientific Officer of Palvella Therapeutics.

The outlook for patients and families is increasingly hopeful. With the first module now under FDA review and a clear path toward completing the application, the goal of delivering the first approved therapy for this lifelong disease is moving closer to reality. The company continues its work with a sense of urgency and responsibility to the community it aims to serve.

FDA Application Microcystic Lymphatic Malformations QTORIN™ Rare Skin Conditions

This article is for informational purposes only and does not constitute medical advice. The information presented is based on published research and official announcements. Always consult a qualified healthcare professional before making any medical decisions.